Maggie L. Shaw

Cranbury

Senior Editor at MJH Life Sciences

Editor

Featured in: Favicon

mjhlifesciences.com Favicon

newsbreak.com Favicon

ajmc.com

contemporaryobgyn.net Favicon

dermatologytimes.com Favicon

contemporarypediatrics.com Favicon

managedhealthcareexecutive.com Favicon

drugtopics.com Favicon

ophthalmologytimes.com Favicon

centerforbiosimilars.com + 3 more

Articles

HIV Self-Testing Clinical Trial Results Prove Feasibility in Application

1 week ago | ajmc.com | Julia Bonavitacola |Maggie L. Shaw |Lynae A. Darbes

Lynae Darbes, PhD, professor in the Department of Health Behavior and Clinical Sciences at the University of Michigan, spoke about how future strategies regarding HIV prevention can be influenced by the findings of her research on self-testing for HIV and providing counsel in couples. TranscriptHow can these findings inform future strategies for integrating couples-based HIV prevention into maternal and child health programs? I believe we showed that our approach is feasible. We had a large sample.
New Hope for IgA Nephropathy With Atrasentan Approval: Richard Lafayette, MD, FACP

1 week ago | ajmc.com | Maggie L. Shaw |Richard Lafayette

On April 2, atrasentan (Vanrafia; Novartis) received an accelerated approval from the FDA for proteinuria reduction in primary immunoglobulin A (IgA) nephropathy, becoming the second “first and only” therapy approved for this purpose in the past month—following iptacopan (Fabhalta) for C3 glomerulopathy on March 20.1,2 This approval of the endothelin A receptor antagonist was based on a prespecified interim analysis of the phase 3 ALIGN study (NCT04573478), which is comparing the efficacy and...
Rusfertide Cuts Phlebotomy Need in Polycythemia Vera: Andrew Kuykendall, MD

2 weeks ago | ajmc.com | Maggie L. Shaw |Andrew Kuykendall

With an expected completion date sometime in June, the phase 3 VERIFY trial (NCT05210790) will soon conclude its investigation of rusfertide (Takeda) as add-on therapy to a patient’s current course of treatment for their polycythemia vera. The investigative agent has already received breakthrough therapy, orphan drug, and fast track designations from the FDA.
Breaking Silos in HIV and Menopause Care: Bridgette Picou, LVN, ACLPN

2 weeks ago | ajmc.com | Maggie L. Shaw |Bridgette Picou

During the “Hot Topic: Menopause and HIV” mini symposia at the 2025 Conference on Retroviruses and Opportunistic Infections, Bridgette J. Picou, LVN, ACLPN, stakeholder liaison, The Well Project, Brooklyn, New York, emphasized the need for more inclusive research on how these 2 aspects of health intersect in women. She spoke to that in part 1 of this interview.
52-Week MINT Data Confirm Inebilizumab Benefit in AChR+ gMG: Richard Nowak, MD, MS

2 weeks ago | ajmc.com | Maggie L. Shaw |Richard J. Nowak

New topline data from the MINT trial (NCT04524273), which is investigating inebilizumab in patients with generalized myasthenia gravis who are acetylcholine receptor (AChR) antibody or muscle-specific kinase (MuSK) positive, have been released.
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score

2 weeks ago | ajmc.com | Maggie L. Shaw

All-cause mortality and clinical worsening events are more likely to occur among patients who have connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) and a Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score of 5 or higher, according to a new study published in BMC Cardiovascular Disorders.1 The study authors explain that patients who have CTD-PAH and left heart dysfunction have greater risk of a worse overall prognosis and that the...
Home-Based Couples Testing Best When Complemented With Counselling

2 weeks ago | ajmc.com | Julia Bonavitacola |Maggie L. Shaw |Lynae A. Darbes

Lynae Darbes, PhD, professor in the Department of Health Behavior and Clinical Sciences at the University of Michigan, discusses research she presented at the 2025 Conference on Retroviruses and Opportunistic Infections that shows home-based counselling was effective in increasing HIV testing along with self-testing kits given to couples. This transcript was lightly edited; captions were auto-generated.
Burden of PAH Weighs Heavy Worldwide

2 weeks ago | ajmc.com | Maggie L. Shaw

Female individuals and older adults, especially if they live in an economically disadvantaged sociodemographic index (SDI) area, are more likely to be adversely affected by pulmonary arterial hypertension (PAH), highlighting the ongoing burden of PAH despite an overall decline in age-standardized incidence rates (ASIRs) of this rare and progressive type of pulmonary hypertension and severe cardiovascular condition.
Radiation Bridging Therapy Boosts CAR T Outcomes in R/R LBCL

3 weeks ago | ajmc.com | Maggie L. Shaw

Patients whose relapsed/refractory large B-cell lymphoma (R/R LBCL) reaches a steady state following radiation bridging therapy during the manufacturing process of their chimeric antigen receptor T-cell (CAR T) are more likely to have positive outcomes following CAR T vs patients with R/R LBCL who instead receive systemic bridging therapy.1Bridging therapy is often required for patients to maintain disease control from when they undergo apheresis to their CAR T infusion, the study authors noted.
Areas of Unmet Need Continue to Burden Patients With gMG

3 weeks ago | ajmc.com | Maggie L. Shaw

Impaired activities of daily living (ADL), fatigue, and reduced ability to work continue to present themselves as areas of unmet need among patients who have generalized myasthenia gravis (gMG), highlighting the significance of patient-reported outcomes measures in facilitating a greater understanding of the chronic autoimmuneneuromuscular disorder by this patient population and the clinicians who treat them.1 New real-world data from an October 2024 cross-sectional survey presented at the...